Efficacy and Tolerance of Urea Compared with Vaptans for Long-Term Treatment of Patients with SIADH | Zendy

Alain Soupart | Zendy; M Coffernils | Zendy; Bruno Couturier | Zendy; Fabrice GankamKengne | Zendy; Guy Decaux | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Tolerance of Urea Compared with Vaptans for Long-Term Treatment of Patients with SIADH

Author(s) -

Alain Soupart,

M Coffernils,

Bruno Couturier,

Fabrice GankamKengne,

Guy Decaux

Publication year - 2012

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.06990711

Subject(s) - medicine , hyponatremia , tolvaptan , tolerability , urea , hypernatremia , gastroenterology , endocrinology , sodium , adverse effect , chemistry , organic chemistry

Vaptans (vasopressin V(2)-receptor antagonists) are a new approach for the treatment of hyponatremia. However, their indications remain to be determined, and their benefit compared with that of the usual treatments for the syndrome of inappropriate antidiuretic hormone secretion (SIADH) have not been evaluated. This prospective, long-term study compared the efficacy, tolerability, and safety of two oral vaptans with those of oral urea in patients with SIADH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research